Jupiter Topco LLC Takes $323.68 Million Position in Amgen Inc. $AMGN

Jupiter Topco LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 893,898 shares of the medical research company’s stock, valued at approximately $323,681,000.

A number of other hedge funds have also bought and sold shares of AMGN. Norges Bank acquired a new stake in shares of Amgen in the fourth quarter valued at about $2,164,162,000. Capital World Investors boosted its holdings in Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. BlackRock Inc. increased its position in Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. State Street Corp increased its position in Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 0.4%

AMGN stock opened at $442.24 on Wednesday. The stock’s 50 day simple moving average is $382.78 and its 200 day simple moving average is $363.35. The company has a market cap of $239.09 billion, a P/E ratio of 27.49, a price-to-earnings-growth ratio of 3.20 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts expect that Amgen Inc. will post 22.92 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald boosted their price target on shares of Amgen from $350.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Barclays lifted their target price on shares of Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research note on Friday, August 14th. Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. BMO Capital Markets upped their price target on shares of Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Finally, Piper Sandler increased their price target on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $380.43.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.